GSK nixes next-gen COVID-19 antibody collaboration, leaving Vir to fly solo, seek new partners

GSK is trimming its ties to Vir Biotechnology, walking away from COVID-19 antibody and vaccine research projects while continuing to collaborate on two pandemic assets and programs against other respiratory diseases.